US2019010518A1PendingUtilityA1

Compositions and Methods of Delivering Treatments for Latent Viral Infections

Assignee: UNIV LELAND STANFORD JUNIORPriority: May 30, 2014Filed: Jan 23, 2018Published: Jan 10, 2019

Est. expiryMay 30, 2034(~7.8 yrs left)· nominal 20-yr term from priority

C12N 2810/60C12N 2310/20C12N 15/86A61K 38/00A61P 31/22C12N 9/22C12Y 301/00A61K 48/005C12N 9/16C12N 15/102A61P 31/14A61P 43/00A61K 38/1761A61K 47/6901A61P 31/20C12N 2330/51C12N 15/1133C12N 15/907A61P 31/18C12N 2310/10C12N 2820/60Y02A50/385Y02A50/463Y02A50/465Y02A50/393Y02A50/387A61P 31/12Y02A50/30

PatentIndex Score

Cited by

References

Claims

Abstract

Viral infection is a persistent cause of human disease. Guided nuclease systems of the invention target the genomes of viral infections, rendering the viruses incapacitated. The invention further provides delivery methods and compositions for antiviral therapeutics. Methods and compositions are provided for targeted delivery of antiviral therapeutics into cells of interest using, for example, viral vectors such as adenovirus, AAV, and replication incompetent HSV. These and other delivery systems can be used as vehicles to deliver DNA vectors encoding a nuclease or a cell-killing gene. These delivery methods can also be used to deliver naked DNA or RNA, protein products, plasmids containing a promoter that is active only in a latent viral state which drives a cell-killing gene, or other therapeutic agents.

Claims

exact text as granted — not AI-modified

1 . A composition comprising guide RNAs for use in the treatment of latent viruses within a cell. 
     
     
         2 - 11 . (canceled)

Join the waitlist — get patent alerts

Track US2019010518A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.